Eris Lifesciences will acquire the remaining 30% stake in its subsidiary, Swiss Parenterals Limited, making it a wholly-owned subsidiary. The acquisition is valued at INR 423.30 crore, to be discharged through a preferential issue of 23,06,372 equity shares. The company also plans a postal ballot to obtain shareholder approval for the preferential issue.
Full Ownership of Swiss Parenterals
Eris Lifesciences has announced its decision to acquire the remaining 30% stake in Swiss Parenterals Limited, thereby achieving 100% ownership of the company. This strategic move aims to enhance operational synergy and strengthen the company’s long-term strategic presence. The Board of Directors approved the acquisition on November 24, 2025.
Deal Rationale
The acquisition is expected to provide complete managerial control, enable full financial consolidation, improve cost efficiencies, and streamline governance. Eris Lifesciences anticipates that this consolidation will enhance shareholder value.
Preferential Issue Details
The consideration for the acquisition, amounting to INR 423.30 crore, will be discharged through the issuance of up to 23,06,372 equity shares of Eris Lifesciences on a preferential basis. These shares will be issued to Mr. Naishadh Shah, a director of Swiss Parenterals. The issue price is determined based on an independent valuation report.
Postal Ballot for Shareholder Approval
Eris Lifesciences will seek shareholder approval via postal ballot for the issuance of shares on a preferential basis to Mr. Naishadh Shah. The cut-off date for determining eligible members for e-voting is set for November 21, 2025.
Swiss Parenterals Performance
Swiss Parenterals, a subsidiary specializing in parenterals, has demonstrated robust performance over the past three fiscal years:
- FY 2022-23: Turnover of INR 220.80 crore
- FY 2023-24: Turnover of INR 282.97 crore
- FY 2024-25: Turnover of INR 351.11 crore
The entity has a presence in over 80 countries.
Source: BSE
